Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone

BACKGROUND: Sublingual tablet buprenorphine (BUP-SL) and oral liquid methadone (MET) are the daily, standard-of-care (SOC) opioid agonist treatment medications for opioid use disorder (OUD). A sizable proportion of the OUD treatment population is not exposed to sufficient treatment to attain the des...

Descripción completa

Detalles Bibliográficos
Autores principales: Marsden, John, Kelleher, Mike, Hoare, Zoë, Hughes, Dyfrig, Bisla, Jatinder, Cape, Angela, Cowden, Fiona, Day, Edward, Dewhurst, Jonathan, Evans, Rachel, Hearn, Andrea, Kelly, Joanna, Lowry, Natalie, McCusker, Martin, Murphy, Caroline, Murray, Robert, Myton, Tracey, Quarshie, Sophie, Scott, Gemma, Turner, Sophie, Vanderwaal, Rob, Wareham, April, Gilvarry, Eilish, Mitcheson, Luke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389497/
https://www.ncbi.nlm.nih.gov/pubmed/35986418
http://dx.doi.org/10.1186/s13063-022-06595-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389497/
https://www.ncbi.nlm.nih.gov/pubmed/35986418
http://dx.doi.org/10.1186/s13063-022-06595-0

Ejemplares similares